CEVEC’s CAP®GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications

  • CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
  • CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vector

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs. Read more

CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US

Cologne, Germany

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications. Read more

CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP(R)GT technology

  • CEVEC’s CAP(R)GT technology enables fully scalable lentiviral and RCA (replication competent adenovirus)-free adenoviral vector production
  • Further step to establish CEVEC’s CAP(R)GT technology as the industrial standard for the production of lentiviral and adenoviral gene therapy vectors

Read more

Use of LiMAx test leads to reduction in post-hepatectomy liver failure and related mortality

Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a retrospective study investigating the impact of the LiMAx test on clinical patient outcome after hepatectomy. Study results showed that the use of the LiMAx test led to reductions in post-operative liver failure and to a decrease of liver failure related mortality. Read more

Helmholtz validation funding extended, facilitating further projects

Developing pioneering technologies and making them attractive for industry often requires a great deal of patience and perseverance. The Helmholtz Validation Fund (HVF) is therefore providing support to a number of particularly promising projects carried out by research teams in the Helmholtz

Association. A total of 21 projects were selected for the first funding period from 2011 to 2015. Following a successful evaluation process, the programme will now continue from 2016 to 2020. The first three projects to be funded in the new programme phase were selected this December by the experts on the decisionmaking board. These projects could pave the way to discovering new and better ways of diagnosing and treating diseases such as cancer, osteoporosis and Alzheimer’s. Read more

Emperra Digital Diabetes Care closes Series B round with Robert Bosch Venture Capital GmbH joining as a new investor

Emperra, a German start-up that has created a digital diabetes management solution consisting of smart hardware and software, has completed a Series B financing round of USD 3.1 million, with Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, joining the existing investors Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Dr. Krey and CTO Dr. Schildt, management of Emperra, also participated in the round. The funds will be used for further product development and to accelerate international growth, predominantly in the United States and Europe. Read more

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies

  • CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies
  • CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing
  • BioLamina to further grow its leading high quality ex vivo cell culture laminin product portfolio
  • First commercial CAP®Go-derived laminin, LN-521, expected to be globally available in 2016

Read more

CEVEC and CellGenix sign collaboration and license agreement for CEVEC’s proprietary CAP®Go technology

Cologne and Freiburg

  • CEVEC provides expertise and grants license for the production of selected growth and differentiation factors based on CAP®Go technology
  • CEVEC further expands CAP®Go applications into the field of GMP-grade ex vivo cell culture products for cell therapies
  • CellGenix provides expertise to develop and manufacture CAP®Go-derived high-quality proteins for clinical cell culture needs
  • CellGenix complements its protein production platform with human expression technology

Read more

CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP®GT technology

  • Agreement enables fully scalable, industrial lentivirus vector production
  • Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications

Read more

CEVEC introduces CAP(R)GT cell-expression system for scalable viral gene therapy vector production

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP(R)GT, for the fully scalable production of gene therapy vectors, based on the Company’s proprietary CAP(R) technology. Read more

PVP expands its portfolio by labfolder – the digital laboratory notebook software for research

Berlin

The Charité Biomedical Fund (CBF-1), managed by Peppermint VenturePartners (PVP), is the lead investor of the current financing round of labfolder – the digital laboratory notebook software for research. labfolder closes a seven-digit growth financing round for further development of the software platform, and expanding marketing and international sales. Read more

CEVEC’s CAP®Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study

  • New CAP(R)Go cell line for the production of glyco-optimized recombinant human alkaline phosphatase successfully established
  • CAP(R)Go derived recombinant human alkaline phosphatase optimized to address therapeutic needs in chronic inflammatory indications and neurodegenerative diseases

Read more

CEVEC grants license to Biotest AG for production of tailor-made glycoproteins

Cologne, Germany

CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP(R)Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients. Read more

Diabetes therapy 2.0 – The Bluetooth-enabled ESYSTA® Smart Insulin Pen and the ESYSTA® smartphone app in the last stages of the CE approval process.

Germany, Potsdam

The Potsdam-based EMPERRA® GmbH E-Health Technologies, specialized in digital health systems and Telediabetology, would like to call your attention to an important further development of the innovative, integrated telemonitoring product system ESYSTA® for insulin-dependent diabetes patients.

ESYSTA-Bluetooth-Insulinpen_web

Read more

CEVEC introduces CAP®Go expression system for scalable production of tailor-made glycoproteins

Cologne, Germany

CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®GO for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® technology.

CAP®Go technology – tailor-made glycosylation of recombinant proteins

With the CAP®Go technology, CEVEC addresses an increasing need in the pharmaceutical and biotechnology industries for the manufacturing of difficult to express therapeutic glycoproteins with tailor-made or fully human glycosylation patterns for significantly improved physicochemical and pharmacological properties.

CEVEC’s CAP®Go expression platform comprises a comprehensive portfolio of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities and allows for the recombinant production of a variety of complexly glycosylated proteins such as high molecular mass multimeric proteins including plasma proteins, coagulation factors, cytokines and antibodies.

In previous studies, CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins. Depending on the selected CAP®Go cell line, the expressed protein showed: increased sialylation for improved half-life; homogenous, serum-like O-glycan structures and/or defined N-glycan antennarity, just to name a few. Therapeutic proteins expressed on conventional mammalian expression platforms like CHO (Chinese hamster ovary) or HEK293 cells (human embryonic kidney cells), by contrast, often do not match the glycosylation and pharmacokinetic profiles of their plasma-purified counterparts. The CAP®Go technology provides a highly economic way to manufacture glyco-optimized proteins with up to 10 fold higher yields than conventional cell lines and offers cost efficient large scale production.

“Our CAP®Go technology brings completely unique features to biopharmaceuticals, placing CEVEC at the leading edge of industrial protein manufacturing,” commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH “The CAP®Go expression platform is designed to manufacture normally ‘difficult to produce’ proteins, coagulation factors and other plasma derived substances as wanted and needed, addressing an increasing demand in the pharmaceutical and biotechnology industry.”

About CEVEC:

Privately held CEVEC is a global solution and service provider for the production of biopharmaceuticals based in Cologne, Germany. The Company’s core technologies, CAP®Go and CAP®GT are based on a unique human cell expression system.
Page 1 of 2
The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express glycoproteins and provide authentic human post- translational modifications. CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins.

The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology form one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP®Go and CAP®GT cells.

CEVEC announces appointment of life sciences industry expert Frank Ubags as Chief Executive Officer

Cologne, Germany

CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.

Frank Ubags joined CEVEC in October 2014 as Chief Operating Officer and Managing Director. He has over 35 years of leadership experience in renowned companies. He has successfully executed major financing transactions, turn around projects, and initiated and executed major M&A transactions in both acquiring and selling companies. Frank joined the life sciences industry in 1997 as CFO of Rhein Biotech, where he led the 1999 IPO and was responsible for the transformation of Rhein Biotech into a vaccines company followed by, two years later, a trade sale to Berna Biotech. In addition, Frank’s experience has included CEO, COO and CFO positions in companies such as the German Rhein Biotech operation, Kiadis Pharma and Scil Proteins. Frank holds several advisory positions in the field of protein production.

Joachim Rautter, Chairman of the CEVEC Supervisory Board, commented: “With Frank’s financial, operational and strategic track record we are well positioned to execute our financing and growth strategies. On behalf of the Board, I would like to thank Wolfgang Kintzel for his excellent work as CEO and his strategic leadership during the last six years.”

“Our CAP(R) Technology is by now very well positioned in the market. It has been specifically developed to enable the industrial scale production of viral vectors for the currently exponentially growing field of gene therapy. In addition, our technology also facilitates limitless access to ‘difficult to produce’ proteins, coagulation factors and other plasma derived substances, allowing for broader, safer and less cost-intensive applications,” explained Frank Ubags, the newly appointed Chief Executive Officer of CEVEC. “Together with the whole CEVEC team, I am looking forward to fully exploit the enormous potential of our unique assets.

First Keratoprosthesis Patient in Europe Receives Permanent 24h Intraocular Pressure Sensor EyeMate

Munich and Hannover, Germany

Implandata Ophthalmic Products GmbH (Implandata) announces the successful implantation of Implandata’s EyeMate intraocular pressure sensor at a first patient in Europe undergoing keratoprosthesis surgery. The implantation was performed by study principal investigator, Prof. Thomas Neuhann, Munich/Germany within sponsor initiated ARGOS-KP01 study. Read more

Humedics closes 6.3 million € financing round

Berlin, Germany Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the closing of a Series C financing round totaling more than 6.3 million Euro. Humedics’ business model, products and company development has attracted new international investors that will join the current private and public investors.

CEVEC Appoints New Management Team

Cologne, Germany Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed Chief Business Officer and Frank Ubags joins as Chief Operating Officer. Read more

IOP Launched Pre-Clinical Studies for 24h Extraocular Sensor

Hannover, Germany Implandata Ophthalmic Products GmbH (Implandata) and Professor Peter Szurman, Head of “Section Experimental Ophthalmic Surgery” at Eye Hospital of University Tübingen, have started pre-clinical studies for the first implantable, permanent extraocular sensor, measuring intraocular pressure. Read more